

Gavi 2016-2020 Strategic Indicators Baselines and Targets

	Indicator	Baseline	Target	Supplemental/detailed baseline data
Aspiration 2020	MA1 Under five mortality rate	64 deaths per 1000 live births	10% reduction	
	MA2 Number of future deaths averted	N/A	5.4 million	
	MA3 Future DALYs averted	N/A	250 million	
	MA4 Number of unique children immunised	N/A	300 million	64.9 million in 2015; 277.8 million 2011-2015; 579.4 million 2001-2015
	MA5 Vaccines sustained after transition	N/A	100%	
Disease Dashboard	D1 Hepatitis B: Number of Gavi 73 countries that have less than 2% hepatitis B surface antigen (HBsAg) prevalence among children less than 5 years of age among countries with surveys meeting inclusion criteria	5 countries out of 6 reporting	N/A – tracked over time	
	D2 Rotavirus: Median proportion (and interquartile range) of acute gastroenteritis hospitalisations positive for rotavirus among children less than one year of age among Gavi countries with any site meeting inclusion criteria	24.2% (19.1%, 41.6%); 25 countries reporting	N/A – tracked over time	
	D3 Measles: Number of Gavi countries reporting an annual measles incidence of less than 5 cases per million population	35 countries out of 70 reporting	N/A – tracked over time	
Strategic goal 1	S1.1 Reach of routine: penta3 and MCV1 coverage	Penta3: 81%; MCV1: 78%	+5 PP for Penta3 and MCV1 from 2016-2020	
	S1.2 Breadth of protection: average coverage across all Gavi supported vaccines	31%	+32 PP from 2016-2020	

Strategic goal 2

<p>S1.3 Geographic distribution: % countries with all districts having ≥80% penta3 coverage</p>	<p>16% (11/68)</p>	<p>+10 PP from 2016-2020</p>	
<p>S1.4 Wealth quintile distribution: % countries in which penta3 coverage in poorest quintile is within 10 percentage points of penta3 coverage in wealthiest quintile</p>	<p>39% (17 of 44 countries with a survey 2011-2015)</p>	<p>+10 PP from 2016-2020</p>	
<p>S1.5 Education: % countries in which penta3 coverage among children whose mothers/female caretakers received no education is within 10 percentage points of coverage among children whose mothers/caretakers have received some education</p>	<p>34% (13 of 38 countries with a survey 2011-2015)</p>	<p>+10 PP from 2016-2020</p>	
<p>S2.1 Supply chain: % countries meeting 80% benchmark for Effective Vaccine Management</p>	<p>16% (11/68)</p>	<p>43% in 2020</p>	
<p>S2.2 Data quality/consistency: % countries with survey in last 5 years and <10 percentage point difference between national administrative coverage and point estimate from survey</p>	<p>43% (20 of 46 countries with a survey 2011-2015)</p>	<p>+10 PP from 2016-2020</p>	
<p>S2.3 Access, demand and service delivery: coverage with first dose of pentavalent vaccine and drop out between first and third dose</p>	<p>Penta1:87%; Drop-out: 6%</p>	<p>Penta1: +4 PP; Drop-out: -3 PP from 2016-2020</p>	

	S2.4 Integration: % countries meeting benchmark for integrated service delivery	26% (18/68 countries)	+10 PP from 2016-2020	Criterion 1: 67%, Criterion 2: 65%
	S2.5 Civil society: % countries meeting benchmark for civil society engagement for improved coverage and equity	To be established pending data source refinements	To be established pending data source refinements	
Strategic goal 3	S3.1 Co-financing: % countries fulfilling commitments	85%	100% in 2020	
	S3.2 Country investment in routine immunisation per child: % countries increasing investment	N/A	100% in 2020 relative to 2015 baseline	
	S3.3 Programmatic sustainability: % countries on track for successful transition	63%	75% in 2020	
	S3.4 Institutional capacity: % countries meeting minimum benchmarks for national decision making, programme management and monitoring	To be established pending data source refinements	To be established pending data source refinements	
Strategic goal 4	S4.1 Sufficient and uninterrupted supply: # vaccine markets where supply meets Gavi demand	7 out of 11	11 out of 11 in 2020	
	S4.2 Reduction in price: price of fully vaccinating child with pentavalent, pneumococcal and rotavirus vaccines	\$20	Not published due to commercial sensitivity	

S4.3 Innovation: # vaccines with improved characteristics procured by Gavi	N/A	10 in 2020	
S4.4 Healthy market dynamics: # vaccine markets with moderate or high healthy market dynamics	1 out of 11	6 out of 11 in 2020	